Correlation between serum concentrations of B-type natriuretic peptide and albumin in patients with chronic congestive heart failure.

While B-type natriuretic peptide (BNP) and hypoalbuminemia are both predictors of major adverse cardiac events (MACE) in patients with congestive heart failure (CHF), whether these markers are correlated is not known. We retrospectively analyzed data collected in 85 patients presenting with CHF, a left ventricular (LV) ejection fraction (EF) < 50%, and non-ischemic heart disease, followed for a mean of 38 months. Statistical analysis was performed to 1) examine the relationship between a) baseline BNP or albumin concentrations and b) baseline clinical characteristics, 2) identify the correlates of changes in (Δ) BNP concentrations, and Δ albumin concentrations, and 3) ascertain the prognostic value of each variable. Log transformed BNP was correlated with New York Heart Association functional class, total protein and LVEF, while albumin was correlated with a history of diabetes mellitus and total protein. Δ BNP and Δ albumin concentrations between baseline and follow-up were correlated (P < 0.0001). The follow-up BNP and albumin concentrations were independent predictors of MACE.BNP and albumin were correlated with different baseline clinical characteristics. The long-term changes in the two markers were inversely correlated and both were independent predictors of CHF.

[1]  S. Anker,et al.  Cachexia in heart disease: highlights from the ESC 2010 , 2011, Journal of cachexia, sarcopenia and muscle.

[2]  S. Moore,et al.  Serum albumin and mortality in acutely decompensated heart failure. , 2010, American heart journal.

[3]  S. Anker,et al.  Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference. , 2010, International journal of cardiology.

[4]  K. Kotani,et al.  A simple risk score to predict in-hospital death of elderly patients with acute decompensated heart failure--hypoalbuminemia as an additional prognostic factor. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[5]  C. Yancy,et al.  Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. , 2008, American heart journal.

[6]  G. Fonarow,et al.  Albumin levels predict survival in patients with systolic heart failure. , 2008, American heart journal.

[7]  Robert H Christenson,et al.  National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. , 2007, Circulation.

[8]  E. Schiffrin,et al.  Chronic Kidney Disease: Effects on the Cardiovascular System , 2007, Circulation.

[9]  S. Solomon,et al.  Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program , 2006, Circulation.

[10]  Hans L. Hillege,et al.  Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.

[11]  S. Anker,et al.  Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. , 2006, International journal of cardiology.

[12]  Cristina Opasich,et al.  Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure: Results From Val-HeFT , 2005, Circulation.

[13]  S. Anker,et al.  The relationship between cholesterol and survival in patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[14]  G. Habib,et al.  Hypoalbuminemia in elderly patients with acute diastolic heart failure. , 2003, Journal of the American College of Cardiology.

[15]  Abdissa Negassa,et al.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.

[16]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[17]  D. Levy,et al.  Obesity and the risk of heart failure. , 2003, The New England journal of medicine.

[18]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.